Chronobiological concepts underlying the chronotherapy of human lung cancer

REFERENCES

• Focan C. Circadian Rhythms and Cancer Chemotherapy. Pharmacol. Ther. 1995; 67(1)1–52
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., Bjarnason G.A. Circadian Cancer Therapy. J. Clin. Oncol. 1993; 11: 1403–1417
   PubMed Web of Science ®Google Scholar
• Lévi F. Chronopharmacology of Anticancer Agents. Handbook of Experimental Pharmacology. Physiology and Pharmacology of Biological Rhythms, P.H. Redfern, B. Lemmer. Springer-Verlag, Berlin 1997; 299–331
   Google Scholar
• Mormont M.C., Boughattas N., Levi F. Mechanisms of Circadian Rhythms in the Toxicity and the Efficacy of Anticancer Drugs: Relevance for the Development of New Analogs. Chronopharmacology Cellular and Biochemical Interactions, B. Lemmer. Marcel Dekker, New York 1989; 395–437
   Google Scholar
• Filipski E., Amat S., Lemaigre G., Vincent M., Breillout F., Levi F. Relationship Between Circadian Rhythm of Vinorelbine Toxicity and Efficacy in P388-Bearing Mice. J. Pharmacol. Exp. Ther. 1999; 289: 231–235
   PubMedGoogle Scholar
• Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., Francois E., Bissery M.C., Levi F. Docetaxel Chronopharmacology in Mice. Cancer Res. 1998; 58: 3896–3904
   PubMed Web of Science ®Google Scholar
• Hashimoto N., Endoh D., Kuwabara M., Satoh H., Sato F. Induction of Lung Tumors in C3H Strain Mice After Single or Fractionated Irradiation with X-Rays. J. Vet. Med. Sci. 1994; 56(3)493–498
   PubMedGoogle Scholar
• Iversen O.H., Kauffman S.L. Circadian Variation in the Susceptibility of Mouse Epidermis to Chemical Carcinogens. Int. J. Chronobiol. 1981; 8(1)49–62
   PubMedGoogle Scholar
• Iversen O.H., Iversen U.M. A Diurnal Variation in the Tumorigenic Response of Mouse Epidermis to a Single Application of the Strong Short-Acting Chemical Carcinogen Methylnitrosourea. A Dose-Response Study of 1, 2 and 10 mg. In Vivo 1995; 9(2)117–132
   PubMedGoogle Scholar
• Mormont M.C., Levi F. Circadian System Alterations During Cancer Processes: A Review. Int. J. Cancer 1997; 70: 241–247
   PubMed Web of Science ®Google Scholar
• Barbason H., De Paermentier F., Van Cantfort J. Molecular Regulatory Mechanisms of Nyctohemeral Rhythms in Hepatic Cell Division and Function. Animal and Environmental Fitness, R. Gilles. Pergamon Press, New York 1980; 145–162
   Google Scholar
• Riabykh T.P., Modianova E.A., Kasatkina N.N., Bodrova N.B. The Carcinogen Urethane Induces High-Amplitudes Circaseptan Variations in Target Tissues and Disrupts the Rhythm of Cell Count in Lymphoïd Organs. Biofizika 1994; 39(5)931–938
   PubMedGoogle Scholar
• Burns E.R., Scheving L.E., Tsai T.H. Circadian Rhythms in DNA Synthesis and Mitotis in Normal Mice and Mice Bearing the Lewis Lung Carcinoma. Eur. J. Cancer 1979; 15(2)233–242
   Google Scholar
• Flentje M., Akokan G., Reinecke D., Klein H.O. Diurnal Variations of Tumor Growth and Its Influence on Cytostatic Treatment. Blut 1981; 43(2)85–88
   PubMedGoogle Scholar
• Hori K., Zhang Q.H., Li H.C., Saito S. Variation of Growth Rate of a Rat Tumour During a Light–Dark Cycle: Correlation with Circadian Fluctuations in Tumour Blood Flow. Br. J. Cancer 1995; 71(6)1163–1168
   PubMedGoogle Scholar
• Perissin L., Zorzet S., Rapozzi V., Carignola R., Angeli A., Giraldi T. Seasonal Effects of Rotational Stress on Lewis Lung Carcinoma Metastasis and T-Lymphocyte Subsets in Mice. Life Sci. 1998; 63(9)711–719
   PubMedGoogle Scholar
• Focan C. Marker Rhythms for Cancer Chronotherapy. From Laboratory Animals to Human Beings. In Vivo 1995; 9: 283–298
   PubMedGoogle Scholar
• Brechot J.M. L'horloge du Cycle Cellulaire et sa Dysrégulation au Cours des Cancers Bronchopulmonaires. Rev. Pneumol. Clin. 1997; 53: 7–11
   PubMedGoogle Scholar
• Focan C. Chronotherapy for Human Solid Tumors Other Than Colorectal. In Vivo 1995; 9(6)549–554
   PubMedGoogle Scholar
• Jager W., Diedrich M., Sauerbrei W., Wildt L. Rhythmic Fluctuations of CEA Serum Levels in Breast Cancer Patients. Anticancer Res. 1987; 7: 711–715
   PubMedGoogle Scholar
• Touitou Y., Focan C. Rhythm in Tumor Markers. Biologic Rhythms in Clinical and Laboratory Medicine, Y. Touitou, E. Haus. Springer-Verlag, Berlin 1992; 648–657
   Google Scholar
• Dogliotti L., Berruti A., Buniva T., Torta M., Bottini A., Tampellini M., Terzolo M., Faggiuolo R., Angeli A. Melatonin and Human Cancer. J. Steroïd Biochem. Mol. Biol. 1990; 37(6)983–987
   PubMedGoogle Scholar
• Bartsch C., Bartsch H., Fluchter S.H., Mecke D., Lippert T.H. Diminished Pineal Function Coïncides with Disturbed Circadian Endocrine Rhythmicity in Untreated Primary Cancer Patients. Ann. NY Acad. Sci. 1994; 719: 502–525
   PubMed Web of Science ®Google Scholar
• Giraldi T., Perissin L., Zorzet S., Rapozzi V. Stress Melatonin and Tumor Progression in Mice. Ann. NY Acad. Sci. 1994; 719: 526–536
   PubMedGoogle Scholar
• Rapozzi, V.; Perissin, L.; Zorzet, S.; Giraldi, T. Effects of Melatonin Administration on Tumor Spread in Mice Bearing Lewis Lung Carcinoma. Pharmacol. Res. 1992; Suppl. 1, 71–72.
   Google Scholar
• Spinazze S., Viviani S., Bidoli P., Rovelli F., Palmer P., Franks C.R., Arienti F., Rivoltini L., Parmiani G. Effect of Prolonged Subcutaneous Administration of Interleukin-2 on the Circadian Rhythms of Cortisol and beta-Endorphin in Advanced Small Cell Lung Cancer Patients. Tumori 1991; 31(77(6))496–499
   Google Scholar
• Viviani S., Bidoli P., Spinazze S., Rovelli F., Lissoni P. Normalization of the Light/Dark Rhythm of Melatonin After Prolonged Subcutaneous Administration of Interleukin-2 in Advanced Small Cell Lung Cancer Patients. J. Pineal Res. 1992; 12(3)114–117
   PubMedGoogle Scholar
• Horai R., Nishihara H., Tateishi R., Matsuda M., Hattori S. Oat-Cell Carcinoma of the Lung Simultaneously Producing ACTH and Serotonin. J. Clin. Endocrinol. Metab. 1973; 37(2)212–219
   PubMedGoogle Scholar
• Chajek T., Romanoff H. Cushing Syndrome with Cyclical Edema and Periodic Secretion of Corticosteroïds. Arch. Intern. Med. 1976; 136(4)441–443
   PubMedGoogle Scholar
• Trump D.L., Abeloff M.D., Hsu T.H. Frequency of Abnormalities of Cortisol Secretion and Water Metabolism in Patients with Cell Carcinoma of the Lung and Other Malignancies. Chest 1982; 81(5)576–580
   PubMedGoogle Scholar
• Miralles Garcia J.M., Outerino D., Garcia-Fernandez A., de Castro del Pozo S., Valentin M.C. Ectopic ACTH Syndrome in Bronchopulmonary Tumors. Med. Clin. (Barc) 1979; 72(1)17–20
   PubMedGoogle Scholar
• Calogero A.E., Minacapilli G., Nicolosi A.M., Marcada M.L., Mistretta A., Latteri S.F., Polosa P., D'Agata R. Limited Clinical Usefulness of Plasma Corticotropin-Releasing Hormone, Adrenocorticotropin and beta-Endorphin Measurements as Markers of Lung Cancer. J. Endocrinol. Invest. 1992; 15(8)581–586
   PubMedGoogle Scholar
• Barni S., Lissoni P., Rovelli F., Crispino S., Paolorossi F., Esposti D., Esposti G., Franchini F., Tancini G. Alteration of Opioid Peptide Circadian Rhythm in Cancer Patients. Tumori 1988; 74(3)357–360
   PubMedGoogle Scholar
• Mazzoccoli G., Giuliani A., Bianco G., De Cata A., Balzanelli M., Carella A.M., La Viola M., Tarquini R. Decreased Serum Levels of Insulin-Like Growth Factor (IGF)-I in Patients with Lung Cancer: Temporal Relationship with Growth Hormone (GH) Levels. Anticancer Res. 1999; 19(2B)1397–1399
   PubMedGoogle Scholar
• Mazzoccoli G., Balzanelli M., Giuliani A., De Cata A., La Viola M., Carella A.M., Bianco G., Tarquini R. Lymphocyte Subpopulations Anomalies in Lung Cancer Patients and Relationship to the Stage of Disease. In Vivo 1999; 13(3)205–209
   PubMedGoogle Scholar
• Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival. J. Natl Cancer Inst. 2000; 92(12)994–1000
   PubMedGoogle Scholar
• Mormont M.C., Waterhouse J., Bleuzen P., Giachetti S., Jami A., Bogdan A., Lellouch J., Misset J.L., Touitou Y., Levi F. Marked 24-h Rest/Activity Rhythms Are Associated with Better Quality of Life, Better Response, and Longer Survival in Patients with Metastatic Colorectal Cancer and Good Performance Status. Clin. Cancer Res. 2000; 6: 3038–3045
   PubMed Web of Science ®Google Scholar
• Nowak R., Mc Millen I.C., Redman J., Short R.V. The Correlation Between Serum and Salivary Melatonin Concentrations and Urinary 6-Hydroxymelatonin Sulphate Excretion Rates: Two Non-invasive Techniques for Monitoring Human Circadian Rhythmicity. Clin. Endocrinol. 1987; 27(4)445–452
   PubMed Web of Science ®Google Scholar
• Bartsch C., Kvetnoy I., Kvetnaia T., Bartsch H., Molotkov A., Franz H., Raikhlin N., Mecke D. Nocturnal Urinary 6-Sulfatoxymelatonin and Proliferating Cell Nuclear Antigen-Immunopositive Tumor Cells Show Strong Positive Correlations in Patients with Gastrointestinal and Lung Cancer. J. Pineal Res. 1997; 23(2)90–96
   PubMedGoogle Scholar
• Levi F., Zidani R., Misset J.L. Randomised Multicentre Trial of Chronotherapy with Oxaliplatin, Fluorouracil, and Folinic Acid in Metastatic Colorectal Cancer. Lancet 1997; 350: 681–686
   PubMed Web of Science ®Google Scholar
• Harris B., Song R., Soong S., Diasio R.B. Relationship Between Dihydropyrimidine Dehydrogenase Activity and Plasma 5-Fluorouracil Levels: Evidence for Circadian Variation of Plasma Drug Levels in Cancer Patients Receiving 5-Fluorouracil by Protracted Continuous Infusion. Cancer Res. 1990; 50: 197–201
   PubMed Web of Science ®Google Scholar
• Focan, C.; Doalto, L.; Mazy, V.; Levi, F.; Bruguerolle, B.; Cano, J. P.; Rahmani, R.; Hecquet, B. 48-hour Continuous Infusion of Vindesine (Followed by Cisplatin) in Advanced Lung Cancer. Chronopharmacokinetic Data and Clinical Efficacy. Bull. Cancer 1989; 76 (8), 909–912.
   Google Scholar
• Hecquet B., Meynadier J., Bonneterre J., Adenis L., Demaille A. Time Dependency in Plasmatic Protein Binding of Cisplatin. Cancer Treat. Rep. 1985; 69: 79–83
   PubMedGoogle Scholar
• Ando Y., Minami H., Sakai S., Shimokata K. Is There a Circadian Variation in Plasma Concentrations of Etoposide Given by Prolonged Continuous Infusion?. Cancer Chemother. Pharmacol. 1996; 37(6)616–618
   PubMedGoogle Scholar
• Nowakowska-Dulawa E. Circadian Rhythm of 5-Fluorouracil (FU) Pharmacokinetics and Tolerance. Chronobiologia 1990; 17: 27–35
   PubMedGoogle Scholar
• Kerr D.J., Lewis C., O'Neil B., Lawson N., Blackie R.G., Newell D.R., Boxall F., Cox J., Rankin E.M., Kaye S.B. The Myelotoxicity of Carboplatin Is Influenced by the Time of Its Administration. Hematol. Oncol. 1990; 8: 59–63
   PubMedGoogle Scholar
• Focan C. Chronotherapy in Lung and Ovarian Cancer. J. Cancer Res. Clin. Oncol. 1990; 116: 1073
   Google Scholar
• Focan C., Bastens B., Driesschaert P., Mendes P., Levi F., Pujol J.L., Thyss A. Circadian Tolerance to Etoposide and Cisplatin as First Line Treatment for Advanced Lung Carcinoma. Ann. Rev. Chronopharmacol. 1990; 7: 219–222
   Google Scholar
• Krakowski I., Levi F., Mechkouri M., Conroy T., Luporsi E., Weber B., Metz R. Dose-Intensity of Etoposide–Cisplatin Depends upon Dosing Time. Ann. Rev. Chronopharmacol. 1988; 5: 373–376
   Google Scholar
• Levi F., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., Chollet P., Itzaki M., Dogliotti L., Iacobelli S., Adam R., Kunstlinger F., Gastiaburu J., Bismuth H., Jasmin C., Misset J.L. Chronomodulated Versus Fixed-Infusion Rate Delivery of Ambulatory Chemotherapy with Oxaliplatin, Fluorouracil and Folinic Acid (Leucovorin) in Patients with Colorectal Cancer Metastases: A Randomized Multiinstitutional Trial. J. Natl Cancer Inst. 1994; 86(21)1608–1617
   PubMed Web of Science ®Google Scholar
• Mohnen L., Heedfeld T., Focan-Henrard D., Kreutz F., Longree L., Focan C. Ambulatory Chrono-chemotherapy by Portable Pumps: Feasibility and Compliance. Nursing Aspects. In Vivo 1995; 9(6)565–571
   PubMedGoogle Scholar
• Focan C. Sequential Chemotherapy and Circadian Rhythm in Human Solid Tumours. A Randomised Trial. Cancer Chemother. Pharmacol. 1979; 3: 197–202
   PubMed Web of Science ®Google Scholar
• Focan C. Chimiothérapie Séquentielle Basée sur L'hypothèse d'un Rythme Circadien de la Prolifération Cellulaire. Nlle Presse Med. 1975; 4: 2709–2712
   PubMedGoogle Scholar
• Focan C., Denis B., Kreutz F., Focan-Henrard D., Levi F. Ambulatory Chronotherapy with 5-Fluorouracil, Folinic Acid, and Carboplatin for Advanced Non small Cell Lung Cancer. A Phase II Feasibility Trial. J. Infus. Chemother. 1995; 5(3 Suppl. 1)148–152
   PubMedGoogle Scholar
• Wang Z., Wan C., Lay Ya., Cornelissen G., Halberg F. Role of Biological Clocks in Normal Conditions, Pathology, and in Therapy. 2. Clinical Chronoradiotherapy of Lung Cancer. Biofizika 1995; 40(5)996–998
   PubMed Web of Science ®Google Scholar